PMID- 27100735
OWN - NLM
STAT- MEDLINE
DCOM- 20170207
LR  - 20221207
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Print)
IS  - 0344-5704 (Linking)
VI  - 77
IP  - 6
DP  - 2016 Jun
TI  - The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus 
      erlotinib-induced interstitial lung disease in patients with advanced pancreatic 
      cancer.
PG  - 1165-70
LID - 10.1007/s00280-016-3026-6 [doi]
AB  - PURPOSE: In a phase III study of gemcitabine plus erlotinib for advanced 
      pancreatic cancer conducted in Canada, the incidence of interstitial lung disease 
      (ILD) was 3.5 %. However, the incidence of ILD was reported as high as 8.5 % in a 
      Japanese phase II study. These results suggest the influence of ethnic factors in 
      the association of the use of gemcitabine plus erlotinib with the incidence of 
      ILD. Here, we conducted a prospective study to analyze the relationship between 
      human leukocyte antigen (HLA) alleles and ILD in Japanese patients with advanced 
      pancreatic cancer receiving gemcitabine plus erlotinib. METHODS: Patients were 
      treated with gemcitabine (1000 mg/m(2); administered by intravenous infusion on 
      days 1, 8, and 15 every 4 weeks) and erlotinib (given orally at 100 mg/day). We 
      compared the frequencies of HLA alleles in patients who did and did not develop 
      ILD. RESULTS: A total of 57 patients were treated, and 4 patients (7.0 %) 
      developed ILD. The combination of HLA-B*15:01 and DRB1*15:01 was observed in 2 of 
      4 patients (50 %) with ILD and in only 1 of 53 patients without ILD (2 %) 
      resulting in odds ratio of 52.0 (95 % CI 3.2-842.5; p = 0.011). CONCLUSION: These 
      results suggest that the combination of HLA-B*15:01 and DRB1*15:01 is associated 
      with ILD in Japanese patients with advanced pancreatic cancer receiving 
      gemcitabine plus erlotinib.
FAU - Nishimura, Meiko
AU  - Nishimura M
AD  - Division of Medical Oncology/Hematology, Kobe University Graduate School of 
      Medicine, Kobe, Japan.
FAU - Toyoda, Masanori
AU  - Toyoda M
AD  - Division of Medical Oncology/Hematology, Kobe University Graduate School of 
      Medicine, Kobe, Japan.
FAU - Takenaka, Kei
AU  - Takenaka K
AD  - Division of Medical Oncology/Hematology, Kobe University Graduate School of 
      Medicine, Kobe, Japan.
FAU - Imamura, Yoshinori
AU  - Imamura Y
AD  - Division of Medical Oncology/Hematology, Kobe University Graduate School of 
      Medicine, Kobe, Japan.
FAU - Chayahara, Naoko
AU  - Chayahara N
AD  - Division of Medical Oncology/Hematology, Kobe University Graduate School of 
      Medicine, Kobe, Japan.
FAU - Kiyota, Naomi
AU  - Kiyota N
AD  - Division of Medical Oncology/Hematology, Kobe University Graduate School of 
      Medicine, Kobe, Japan.
FAU - Mukohara, Toru
AU  - Mukohara T
AD  - Division of Medical Oncology/Hematology, Kobe University Graduate School of 
      Medicine, Kobe, Japan.
AD  - Cancer Center, Kobe University Hospital, Kobe, Japan.
FAU - Kotake, Takeshi
AU  - Kotake T
AD  - Department of Medical Oncology, Kobe City Hospital Organization, Kobe City 
      Medical Center General Hospital, Kobe, Japan.
AD  - Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan.
FAU - Tsuji, Akihito
AU  - Tsuji A
AD  - Department of Medical Oncology, Kobe City Hospital Organization, Kobe City 
      Medical Center General Hospital, Kobe, Japan.
AD  - Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kagawa, 
      Japan.
FAU - Saito, Kosuke
AU  - Saito K
AD  - Division of Medicinal Safety Science, National Institute of Health Sciences, 
      Tokyo, Japan.
FAU - Saito, Yoshiro
AU  - Saito Y
AD  - Division of Medicinal Safety Science, National Institute of Health Sciences, 
      Tokyo, Japan.
FAU - Minami, Hironobu
AU  - Minami H
AD  - Division of Medical Oncology/Hematology, Kobe University Graduate School of 
      Medicine, Kobe, Japan. hminami@med.kobe-u.ac.jp.
AD  - Cancer Center, Kobe University Hospital, Kobe, Japan. hminami@med.kobe-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160421
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (HLA-B protein, human)
RN  - 0 (HLA-B27 Antigen)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-DRB1*15:01 antigen)
RN  - 0W860991D6 (Deoxycytidine)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Deoxycytidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Drug Administration Schedule
MH  - Erlotinib Hydrochloride/administration & dosage/*adverse effects/therapeutic use
MH  - Female
MH  - Gene Frequency
MH  - HLA-B27 Antigen/*genetics
MH  - HLA-DRB1 Chains/*genetics
MH  - Humans
MH  - Infusions, Intravenous
MH  - Japan
MH  - Lung Diseases, Interstitial/*chemically induced/genetics
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Pancreatic Neoplasms/*drug therapy/genetics/pathology
MH  - Prospective Studies
MH  - Young Adult
MH  - Gemcitabine
PMC - PMC4882349
OTO - NOTNLM
OT  - Erlotinib
OT  - Gemcitabine
OT  - Human leukocyte antigen
OT  - Interstitial lung disease
OT  - Pancreatic cancer
EDAT- 2016/04/22 06:00
MHDA- 2017/02/09 06:00
PMCR- 2016/04/21
CRDT- 2016/04/22 06:00
PHST- 2016/03/01 00:00 [received]
PHST- 2016/03/28 00:00 [accepted]
PHST- 2016/04/22 06:00 [entrez]
PHST- 2016/04/22 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
PHST- 2016/04/21 00:00 [pmc-release]
AID - 10.1007/s00280-016-3026-6 [pii]
AID - 3026 [pii]
AID - 10.1007/s00280-016-3026-6 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2016 Jun;77(6):1165-70. doi: 
      10.1007/s00280-016-3026-6. Epub 2016 Apr 21.